Effects of Socioeconomic Factors on Visual Outcome and Management of Wet Age-Related Macular Degeneration Patients.

IF 2.1 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2025-08-26 DOI:10.1097/IAE.0000000000004649

Normila Barthelemy, Prashant Tailor, Jayanth Sridhar, Thilani Samarakoon, Jesse D Sengillo

{"title":"Effects of Socioeconomic Factors on Visual Outcome and Management of Wet Age-Related Macular Degeneration Patients.","authors":"Normila Barthelemy, Prashant Tailor, Jayanth Sridhar, Thilani Samarakoon, Jesse D Sengillo","doi":"10.1097/IAE.0000000000004649","DOIUrl":null,"url":null,"abstract":"Purpose: To analyze the relationship between socioeconomic status (SES) and neovascular age-related macular degeneration (nAMD) outcomes and management.Methods: Retrospective analysis of 1449 patients diagnosed with nAMD, treated with anti-VEGF between January 2016-January 2024.Results: Lower income was associated with poorer baseline (p < .001) and final (p < .001) BCVA. Worse final visual acuity correlated with lower baseline BCVA (p < .001), lower income (p = .05) and older age (p < .001); insurance type did not (p = .558). Non-Hispanic/non-Latino patients exhibited a higher rate of delayed injections per scheduled visit than Hispanics (p =.002). Ethnicity correlated with insurance status (p = .008); Hispanic or Latino patients more often had Medicaid or commercial insurance; non-Hispanics/non-Latino patients more often had Medicare. Higher-income patients were more likely to receive aflibercept (p < .001) and faricimab (p =.021). Hispanic or Latino were more likely to receive bevacizumab (OR 2.49; p < .001), but insurance type modified this association (OR 3.42; p = .010).Conclusions: Lower income correlated with worse nAMD visual outcomes, and the type of anti-VEGF treatment used varied across income and ethnicity groups, but not insurance type.","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004649","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To analyze the relationship between socioeconomic status (SES) and neovascular age-related macular degeneration (nAMD) outcomes and management.

Methods: Retrospective analysis of 1449 patients diagnosed with nAMD, treated with anti-VEGF between January 2016-January 2024.

Results: Lower income was associated with poorer baseline (p < .001) and final (p < .001) BCVA. Worse final visual acuity correlated with lower baseline BCVA (p < .001), lower income (p = .05) and older age (p < .001); insurance type did not (p = .558). Non-Hispanic/non-Latino patients exhibited a higher rate of delayed injections per scheduled visit than Hispanics (p =.002). Ethnicity correlated with insurance status (p = .008); Hispanic or Latino patients more often had Medicaid or commercial insurance; non-Hispanics/non-Latino patients more often had Medicare. Higher-income patients were more likely to receive aflibercept (p < .001) and faricimab (p =.021). Hispanic or Latino were more likely to receive bevacizumab (OR 2.49; p < .001), but insurance type modified this association (OR 3.42; p = .010).

Conclusions: Lower income correlated with worse nAMD visual outcomes, and the type of anti-VEGF treatment used varied across income and ethnicity groups, but not insurance type.

查看原文本刊更多论文

社会经济因素对湿性年龄相关性黄斑变性患者视力结局和治疗的影响。

目的：分析社会经济地位（SES）与新生血管性年龄相关性黄斑变性（nAMD）预后及治疗的关系。方法：回顾性分析2016年1月至2024年1月期间1449例诊断为nAMD并接受抗vegf治疗的患者。结果：较低的收入与较差的基线（p < 0.001）和最终（p < 0.001） BCVA相关。最终视力较差与基线BCVA较低（p < 0.001）、收入较低（p = 0.05）和年龄较大（p < 0.001）相关；保险类型与此无关（p = .558）。非西班牙裔/非拉丁裔患者的延迟注射率高于西班牙裔患者（p = 0.002）。种族与保险状况相关（p = 0.008）；西班牙裔或拉丁裔患者通常有医疗补助或商业保险；非西班牙裔/非拉丁裔患者通常有医疗保险。收入较高的患者更可能接受阿伯西普（p < 0.001）和法利昔单抗（p = 0.021）。西班牙裔或拉丁裔更有可能接受贝伐单抗（or 2.49; p < .001），但保险类型改变了这种关联（or 3.42; p = .010）。结论：较低的收入与较差的nAMD视力结果相关，使用的抗vegf治疗类型因收入和种族而异，但保险类型没有差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.